The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism

International Journal of Cancer

Volumn 134, Issue 11, 2014, Pages 2560-2571

  Jeannot, Victor ^a,b   Busser, Benoît ^a,b,c   Brambilla, Elisabeth ^a,b,c   Wislez, Marie ^d,e   Robin, Blaise ^a,b   Cadranel, Jacques ^d,e   Coll, Jean Luc ^a,b   Hurbin, Amandine ^a,b  

^a INSTITUT ALBERT BONNIOT   (France)

^b UNIV GRENOBLE ALPES   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d HÔPITAL TENON   (France)

^e Intergroupe Francophone de Cancérologie Thoracique IFCT   (France)

Author keywords

EGFR TKI resistance; IGF1R; lung cancer; PI3K AKT; sirtuins

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; AMPHIREGULIN; GEFITINIB; KU ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN KINASE B; SHORT HAIRPIN RNA; SIRTUIN; SOMATOMEDIN C RECEPTOR;

AGED; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; VERY ELDERLY;

EGFR-TKI RESISTANCE; IGF1R; LUNG CANCER; PI3K-AKT; SIRTUINS;

ACETYLATION; ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NUCLEAR; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL PROLIFERATION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HISTONE DEACETYLASE 1; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUTATION; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHORYLATION; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; TUMOR CELLS, CULTURED;

EID: 84896365150     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28594     Document Type: Article

References (53)

1. Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004; 15: 28-32.
2. Hirsch FR, Janne PA, Eberhardt WE, et al. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol 2013; 8: 373-84.
3. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors. Sci Transl Med 2011; 3: 75ra26.
4. Busser B, Sancey L, Brambilla E, et al. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta Rev Cancer 2011; 1816: 119-31.
5. Hurbin A, Coll JL, Dubrez-Daloz L, et al. Cooperation of amphiregulin and insulin-like growth factor-1 inhibits Bax- and Bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells. J Biol Chem 2005; 280: 19757-67.
6. Hurbin A, Dubrez L, Coll JL, et al. Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines. J Biol Chem 2002; 277: 49127-33.
7. Busser B, Sancey L, Josserand V, et al. Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers. Mol Ther 2010; 18: 528-35.
8. Hurbin A, Wislez M, Busser B, et al. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma. J Pathol 2011; 225: 83-95.
9. Cadranel J, Quoix E, Baudrin L, et al. IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype. J Thorac Oncol 2009; 4: 1126-35.
10. Busser B, Sancey L, Josserand V, et al. Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation. Mol Ther 2010; 18: 536-43.
11. Dobashi Y, Suzuki S, Kimura M, et al. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas. Hum Pathol 2011; 42: 214-26.
12. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-43.
13. Yamasaki F, Johansen MJ, Zhang D, et al. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res 2007; 67: 5779-88.
14. Li H, Schmid-Bindert G, Wang D, et al. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Adv Med Sci 2011; 56: 275-84.
15. Barneda-Zahonero B, Parra M,. Histone deacetylases and cancer. Mol Oncol 2012.
16. Osada H, Tatematsu Y, Saito H, et al. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 2004; 112: 26-32.
17. Cohen HY, Lavu S, Bitterman KJ, et al. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. Mol Cell 2004; 13: 627-38.
18. Subramanian C, Jarzembowski JA, Opipari AW, Jr, et al. HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma. Neoplasia 2011; 13: 726-34.
19. Dowdy SC, Jiang S, Zhou XC, et al. Histone deacetylase inhibitors and paclitaxel cause synergistic effects on apoptosis and microtubule stabilization in papillary serous endometrial cancer cells. Mol Cancer Ther 2006; 5: 2767-76.
20. North BJ, Marshall BL, Borra MT, et al. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 2003; 11: 437-44.
21. Archer SY, Meng S, Shei A, et al. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 1998; 95: 6791-6.
22. Altomare DA, Testa JR,. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24: 7455-64.
23. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR,. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005; 94: 29-86.
24. Brognard J, Clark AS, Ni Y, et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001; 61: 3986-97.
25. Shah A, Swain WA, Richardson D, et al. Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11: 2930-6.
26. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2004; 96: 1133-41.
27. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005; 2: e17.
28. Laurent-Puig P, Lievre A, Blons H,. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 2009; 15: 1133-9.
29. Roberts PJ, Stinchcombe TE, Der CJ, et al. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy J Clin Oncol 2010; 28: 4769-77.
30. Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst 2012; 104: 228-39.
31. Gama V, Gomez JA, Mayo LD, et al. Hdm2 is a ubiquitin ligase of Ku70-Akt promotes cell survival by inhibiting Hdm2-dependent Ku70 destabilization. Cell Death Differ 2009; 16: 758-69.
32. Jung KH, Noh JH, Kim JK, et al. HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J Cell Biochem 2012; 113: 2167-77.
33. Vannini A, Volpari C, Filocamo G, et al. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc Natl Acad Sci USA 2004; 101: 15064-9.
34. Minamiya Y, Ono T, Saito H, et al. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer 2011; 74: 300-4.
35. Di Marcotullio L, Canettieri G, Infante P, Greco A, Gulino A,. Protected from the inside: endogenous histone deacetylase inhibitors and the road to cancer. Biochim Biophys Acta 2011; 1815: 241-52.
36. Haigis MC, Sinclair DA,. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 2010; 5: 253-95.
37. Jeong J, Juhn K, Lee H, et al. SIRT1 promotes DNA repair activity and deacetylation of Ku70. Exp Mol Med 2007; 39: 8-13.
38. Sundaresan NR, Samant SA, Pillai VB, et al. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol 2008; 28: 6384-401.
39. Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305: 390-2.
40. Tseng RC, Lee CC, Hsu HS, et al. Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. Neoplasia 2009; 11: 763-70.
41. Amsel AD, Rathaus M, Kronman N, et al. Regulation of the proapoptotic factor Bax by Ku70-dependent deubiquitylation. Proc Natl Acad Sci USA 2008; 105: 5117-22.
42. Boyault C, Sadoul K, Pabion M, et al. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 2007; 26: 5468-76.
43. Oehme I, Linke JP, Bock BC, et al. Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc Natl Acad Sci USA 2013; 110: E2592-601.
44. Butler KV, Kalin J, Brochier C, et al. Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A. J Am Chem Soc 2010; 132: 10842-6.
45. Zuo Q, Wu W, Li X, et al. HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin. Oncol Rep 2012; 27: 819-24.
46. Cea M, Soncini D, Fruscione F, et al. Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PLoS One 2011; 6: e22739.
47. Sundaresan NR, Pillai VB, Wolfgeher D, et al. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal 2011; 4: ra46.
48. Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-44.
49. Courtney KD, Corcoran RB, Engelman JA,. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010; 28: 1075-83.
50. Hennessy BT, Lu Y, Poradosu E, et al. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 2007; 13: 7421-31.
51. Garrett CR, Coppola D, Wenham RM, et al. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest New Drugs 2011; 29: 1381-9.
52. Bendell JC, Rodon J, Burris HA, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30: 282-90.
53. Chandarlapaty S, Sawai A, Scaltriti M, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011; 19: 58-71.